Business
BioVie Announces Registration Details for "BioVie Day" Webinar
Virtual Webinar to be held March 23, 2023, at 10:00am Eastern Time CARSON CITY, Nev., March 14, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie”
About this update from Biovie Inc.
[{"type":"text","content":"Virtual Webinar to be held March 23, 2023, at 10:00am Eastern Time\nCARSON CITY, Nev., March 14, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced registration details for BioVie Day—a virtual webinar to be held March 23, 2023 at 10 a.m. Eastern Standard Time. BioVie Day will feature a comprehensive overview of the Company’s programs in Alzheimer’s Disease, Parkinson’s Disease, Epigenetics & Longevity, and Liver Disease, including the following topics: Overview of chronic low-grade inflammation and its impact on disease pathologyUpdates on Alzheimer’s, Parkinson’s, Epigenetics & Longevity, and Liver Disease clinical programs Clinical and regulatory strategyApproach to partnerships and commercializationSocial Impact A live question and answer session will follow the leadership teams’ formal presentations. To register for BioVie Day, please click here. About BioVie BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer’s and Parkinson’s diseases. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing NE3107-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trial in Alzheimer’s Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer’s. A Phase 2 study of NE3107 in Parkinson’s disease (NCT05083260) has completed, and topline data released in December 2022, showed clinically meaningful improvement in motor control in patients treated with a combination of...